

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1 – 45. (canceled)

46. (currently amended) A dosage form comprising:

an osmotic core within an internal compartment comprising a therapeutic agent;

a first membrane ~~in contact with said osmotic core~~, surrounding the internal compartment, the first membrane having a permeability and comprising a hydrophobic substance and a hydrophilic substance, the hydrophilic substance exhibiting an aqueous solubility responsive to osmotic pressure ~~and/or ionic strength~~ of said osmotic core;

a second membrane comprising a semipermeable composition positioned over an outside surface of said first membrane, wherein the second membrane maintains its physical and chemical integrity as the dosage form dispenses the therapeutic agent; and

at least one passageway formed across the membranes for dispensing the therapeutic agent from the dosage form.

47-50. (canceled)

51. (original) The dosage form of claim 46, wherein the integrity of the first membrane degrades during operation of the dosage form.

52-53. (canceled)

54. (original) The dosage form of claim 46, wherein the first membrane is formulated such that the permeability of the first membrane increases in response to a decrease in osmotic pressure.

55. (previously presented) The dosage form of claim 46, wherein the osmotic core, the first membrane, and the second membrane are formulated and configured to deliver the therapeutic agent in an extended, non-declining release profile.

56. (original) The dosage form of claim 55, wherein the extended, non-declining release profile comprises a period of about 30 minutes to about 24 hours.

57. (original) The dosage form of claim 55, wherein the extended, non-declining release profile comprises a period of about 4 hours to about 24 hours.

58. (previously presented) The dosage form of claim 46, wherein the osmotic core, the first membrane, and the second membrane, are formulated and configured to deliver the therapeutic agent in a zero-order release profile.

59. (original) The dosage form of claim 46, further comprising an expandable layer.

60. (currently amended) A method of delivering a therapeutic agent to a subject, the method comprising:

administering a dosage form to the subject, the dosage form comprising:

an osmotic core within an internal compartment including the therapeutic agent,

a first membrane ~~in contact with the osmotic core~~ surrounding the internal compartment,
the first membrane having a permeability and comprising a hydrophobic substance and a hydrophilic substance, the hydrophilic substance exhibiting an aqueous solubility responsive to osmotic pressure ~~and/or ionic strength~~ of said osmotic core, and

a second membrane comprising a semipermeable composition positioned over an outside surface of said first membrane, wherein the second membrane maintains its physical and chemical integrity as the dosage form dispenses the therapeutic agent, and

at least one passageway formed across the membranes for dispensing the therapeutic agent from the dosage form.